Iron Chelation Drug Market
Summary
The rationale behind using Iron chelation therapy is removing the increased iron burden specifically labile cell iron (LCI) to minimize production of reactive oxygen species (ROS) thereby decreasing cellular and organ damage. Patients most likely to benefit from chelation therapy include those with low or intermediate-1 IPSS risk MDS who have a long-life expectancy and are anticipated to receive more than 20 red blood cell transfusions and/or whose serum ferritin level is >1000 ?g/L. Chelation therapy efficacy can be monitored by monitoring trends and levels of serum ferritin.
The global Iron Chelation Drug market is expected to reach xxx Million USD by 2025, with a CAGR of xx% from 2020 to 2025.
Further key aspects of the report indicate that:
Chapter 1: Market Definition and Segment by Type, End-Use & Major Regions Market Size
Chapter 2: Global Production & Consumption Market by Type and End-Use
Chapter 3: Europe Production & Consumption Market by Type and End-Use
Chapter 4: America Production & Consumption Market by Type and End-Use
Chapter 5: Asia Production & Consumption Market by Type and End-Use
Chapter 6: Oceania Production & Consumption Market by Type and End-Use
Chapter 7: Africa Production & Consumption Market by Type and End-Use
Chapter 8: Global Market Forecast by Type, End-Use and Region
Chapter 9: Company information, Sales, Cost, Margin, news etc.
Chapter 10: Market Competition by Companies and Market Concentration Ratio
Chapter 11: Market Impact by Coronavirus.
Chapter 12: Industry Summary
.
Market Segment as follows:
Key Companies:
Apotex Inc. (Canada)
Cipla (India)
Novartis (Switzerland)
Sun Pharma (India)
Natco Pharma (India)
Key Types
Deferoxamine
Deferiprone
Deferasirox
Key End-Use
Transfusional Iron Overload
NTDT Caused Iron Overload
This report can be dispatched within 24-48 Hours.